Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 10 years, with Q3 2025 value amounting to $5.4 million.

  • Viridian Therapeutics, Inc.\DE's Non Operating Income fell 2027.68% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 72.81%. This contributed to the annual value of $29.1 million for FY2024, which is 7400.1% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Non Operating Income stood at $5.4 million, which was down 2027.68% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Non Operating Income ranged from a high of $7.7 million in Q4 2024 and a low of $34000.0 during Q2 2021
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Non Operating Income had a median value of $4.2 million in 2023 and averaged $3.6 million.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Non Operating Income crashed by 4210.53% in 2021 and then soared by 566986.3% in 2023.
  • Viridian Therapeutics, Inc.\DE's Non Operating Income (Quarter) stood at $135000.0 in 2021, then surged by 2330.37% to $3.3 million in 2022, then soared by 40.75% to $4.6 million in 2023, then skyrocketed by 67.76% to $7.7 million in 2024, then tumbled by 30.11% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $6.0 million for Q2 2025, and $7.0 million during Q1 2025.